Aardvark Therapeutics (AARD) Shares Outstanding (2024 - 2026)
Aardvark Therapeutics (AARD) posted Shares Outstanding (Entity) of $21.8 million for Q1 2026, little changed sequentially from $21.8 million in Q4 2025, and up 65.34% YoY from $13.2 million in Q1 2025.
Aardvark Therapeutics (AARD) Shares Outstanding (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Shares Outstanding (Entity) for 3 years, with the latest figure at $21.8 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 65.34% year-over-year to $21.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.8 million (up 65.34% YoY) and the FY2025 annual result came in at $21.8 million, up 436.4% from the prior year.
- Shares Outstanding (Entity) was little changed at $21.8 million in Q1 2026 per AARD's latest filing, from $21.8 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $21.8 million in Q1 2026 and troughed at $4.0 million in Q1 2024.
- A 3-year average of $12.9 million and a median of $13.2 million in 2025 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) soared 446.7% in 2025, then surged 65.34% in 2026.
- Over 3 years, Shares Outstanding (Entity) stood at $4.1 million in 2024, then jumped by 436.4% to $21.8 million in 2025, then grew by 0.0% to $21.8 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $21.8 million, $21.8 million, and $21.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 21.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.85 Mn |
| Mar 31, 2026 | 21.82 Mn |
| Dec 31, 2025 | 19.62 Mn |
| Sep 30, 2025 | 21.71 Mn |
| Jun 30, 2025 | 21.69 Mn |
| Mar 31, 2025 | 13.19 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Jun 30, 2024 | 3.97 Mn |
| Mar 31, 2024 | 3.97 Mn |